Howard Capital Management Inc. Grows Position in DexCom, Inc. (NASDAQ:DXCM)

Howard Capital Management Inc. grew its stake in DexCom, Inc. (NASDAQ:DXCM) by 3.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,921 shares of the medical device company’s stock after acquiring an additional 317 shares during the quarter. Howard Capital Management Inc.’s holdings in DexCom were worth $849,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the stock. Jennison Associates LLC raised its stake in DexCom by 1,683.2% in the 3rd quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock valued at $464,782,000 after purchasing an additional 6,544,102 shares during the last quarter. Congress Asset Management Co. grew its holdings in shares of DexCom by 5,456.9% during the fourth quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company’s stock worth $105,529,000 after buying an additional 1,332,522 shares in the last quarter. Fisher Funds Management LTD acquired a new position in shares of DexCom in the fourth quarter valued at approximately $96,507,000. Westfield Capital Management Co. LP lifted its stake in shares of DexCom by 44.6% during the third quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock valued at $190,532,000 after buying an additional 876,739 shares during the period. Finally, Two Sigma Advisers LP boosted its position in DexCom by 182.7% during the third quarter. Two Sigma Advisers LP now owns 1,143,476 shares of the medical device company’s stock worth $76,659,000 after acquiring an additional 739,000 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on DXCM shares. Canaccord Genuity Group boosted their price target on DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a report on Friday, February 14th. StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and raised their price target for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Wells Fargo & Company upped their price objective on shares of DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Finally, Baird R W raised shares of DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Four research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $99.06.

DexCom Trading Down 0.6 %

NASDAQ:DXCM opened at $88.78 on Monday. The business’s 50-day moving average is $83.50 and its two-hundred day moving average is $76.06. The firm has a market capitalization of $34.69 billion, a PE ratio of 62.08, a price-to-earnings-growth ratio of 2.30 and a beta of 1.14. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Research analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Jereme M. Sylvain sold 2,090 shares of DexCom stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the sale, the executive vice president now directly owns 83,526 shares of the company’s stock, valued at approximately $7,259,244.66. The trade was a 2.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the transaction, the chief executive officer now directly owns 319,037 shares of the company’s stock, valued at $27,727,505.67. This represents a 9.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 38,083 shares of company stock worth $3,309,794 over the last 90 days. Company insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.